Last reviewed · How we verify
pneumococcal disease prevention — Competitive Intelligence Brief
phase 3
Biologic
Live · refreshed every 30 min
Target snapshot
pneumococcal disease prevention (pneumococcal disease prevention) — Beijing Minhai Biotechnology Co., Ltd. Stimulates the immune system to produce antibodies against Streptococcus pneumoniae capsular polysaccharides.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pneumococcal disease prevention TARGET | pneumococcal disease prevention | Beijing Minhai Biotechnology Co., Ltd | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pneumococcal disease prevention CI watch — RSS
- pneumococcal disease prevention CI watch — Atom
- pneumococcal disease prevention CI watch — JSON
- pneumococcal disease prevention alone — RSS
Cite this brief
Drug Landscape (2026). pneumococcal disease prevention — Competitive Intelligence Brief. https://druglandscape.com/ci/pneumococcal-disease-prevention. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing